Boehringer Ingelheim has completed a trifecta of approvals for its blood thinner Pradaxa for deep vein thrombosis and pulmonary embolism. The U.K. cost watchdog NICE has now given it a thumbs up after the FDA and the European regulators did the same thing this year.
About 240 workers at a Boehringer Ingelheim complex in Virginia will have something special to celebrate this Thanksgiving: the prospect of keeping their jobs. Just weeks ahead of closing the facility and laying off all its workers, Boehringer has found a Chinese buyer that intends to add to the headcount there.
Boehringer Ingelheim has completed a pilot project to assess whether it is best served by its current electronic laboratory notebook technology. The process led to Boehringer deciding to phase out use of multiple in-house systems and replace them with IDBS' E‑WorkBook Suite.
The newly public Vitae reported after the market closed on Thursday that the oral BI1181181/VTP-37948 hit the goal posts on a key biomarker for BACE, or beta secretase, flushing a prime suspect behind the disease without triggering any red safety flags in a pair of Phase I studies among a small group of healthy volunteers.
When it comes to the makings of a market-share showdown, the idiopathic pulmonary fibrosis (IPF) landscape has it all. Same-day FDA approvals? Check. A patient population never before reached by pharma? Check. Nearly identical price tags? As of this week, that's a check, too.
There's nothing like same-day FDA approvals to trigger a market showdown--and that's the case for a pair of new idiopathic pulmonary fibrosis (IPF) treatments. After snagging nods from the agency Wednesday, Roche's Esbriet and Boehringer Ingelhem's Ofev will be going head-to-head.
InterMune and Boehringer Ingelheim have spent the last year or so jockeying for the spotlight with in-development treatments for a rare lung disease, hoping to take pole position upon reaching the market. Now, as the FDA has decided to approve both drugs at once, the two companies will set off from equal starting points in the race for dominance.
Boehringer Ingelheim envisions some day selling day a smart inhaler that can tell patients when its medication is running low and remind them if they missed a prescheduled dose.
Boehringer Ingelheim has added a subproject to the expansion of its Respimat production plant in Dortmund, Germany.
When Europe's drug approval gatekeepers meet, they often tick off recommendations for some key Big Pharma products. This week, the Committee for Medicinal Products for Human Use backed a whopping 15 new meds and 3 new indications.